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ABSTRACT
Current treatments for glioblastoma (GBM) have limited efficacy and significant morbidity and therefore
new strategies are urgently needed. Dendritic cells have the power to create anti-tumor immune
responses. The greater potency of circulating dendritic cells (DC) over laboratory-generated monocyte-
derived DC makes them exciting new immunotherapeutic candidates. To determine the immune status
of GBM patients we initially investigated the frequency and function of circulating DC subsets.
Furthermore, we tested the therapeutic potential of inhibiting the p38 mitogen-activated protein kinase
pathway (p38i) in circulating DC to overcome DC dysfunction.
GBM patients (n = 16) had significantly reduced numbers of the major myeloid circulating
dendritic cell (cDC2) and plasmacytoid DC vs healthy controls; 1736 vs 4975 (p = 0.028) and 893
vs 2287 cells/mL (P = <0.001) respectively. This inversely correlated with dexamethasone (Dex) dose
in a log-linear model, and disease status. Patients’ cDC2 were immature with impaired interleukin
(IL)-12 secretion, reduced IL-12:IL-10 ratio, and low HLA-DR and CD86 expression. Exposure of
healthy donor cDC2 to Dex or GBM cell lysate resulted in a similar low IL-12:IL-10 ratio. Inhibition
of p38 restored the IL-12:IL-10 balance in Dex or tumor lysate-conditioned healthy cDC2 and
enhanced T-cell proliferation and interferon-gamma (IFNγ) production. Importantly, patient-derived
cDC2 showed a similar reversal of DC dysfunction with p38i. This study demonstrates the therapeu-
tic potential of developing the next generation of DC vaccines using enhanced p38i-conditioned
cDC2. We will therefore shortly embark on a clinical trial of adoptively transferred, p38 MAPK-
inhibited cDC2 in adults with GBM.
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Introduction
Glioblastoma Multiforme (GBM), the most common pri-
mary malignant brain tumor in adults, is a devastating dis-
ease that inevitably becomes resistant to surgery,
chemotherapy, and radiation. The extraordinary power of
enhancing the immune system to combat the chemo-
radiotherapy resistant tumor, melanoma, affirms the poten-
tial for re-directing immune responses against GBM.
Furthermore, such approaches have the added advantage of
combining initial anti-cancer cytotoxic immunity with dur-
able memory responses.1,2
Dendritic cells (DC) play a central role in the anti-
cancer immune cycle3 orchestrating adaptive immune
responses by antigen uptake, presentation, and co-
stimulation of effector T cells. They are, therefore, critical
for the detection of cancers as “dangerous” and initiating
antigen-specific T-cell responses.4 Additionally, DC control
the cytotoxic activity of, and interferon-gamma (IFNγ)
production by, natural killer (NK) cells, which also serve
important roles against cancer.5 However, tumors have
evolved numerous mechanisms to suppress DC function
and evade immune recognition.6,7
In GBM patients, the hostile tumor microenvironment
comprises, amongst other factors, interleukin (IL)-10, trans-
forming growth factor-beta (TGF-β), and indoleamine
2,3-dioxygenase (IDO), which potently suppress the func-
tion of DC.6,8 Furthermore, this patient group is often
treated with corticosteroids, mainly dexamethasone (Dex),
to control cerebral edema. Such corticosteroids markedly
impact on DC differentiation, maturation, cytokine secre-
tion and induction of lymphocyte responses.9,10 These
effects are seen with laboratory-generated, monocyte-
derived DC (moDC) and have also shown to decrease
circulating myeloid and plasmacytoid DC (pDC) numbers
in non-cancer patients.10
Current strategies to overcome this DC immune dysfunc-
tion in GBM have focussed on the adoptive transfer of ex-vivo
generated autologous moDC.11-13 However, clinical results in
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several tumor types, including glioma, have been disappoint-
ing, with benefit only seen in selected patients, and objective
response rates rarely exceed 15%.14 Therefore, recent interest
has turned to using primary circulating DC isolated directly
from peripheral blood. These have been shown in experimen-
tal systems to be superior to moDC in activating the adaptive
immune response.
There is a paucity of data concerning circulating DC in GBM.
The distinct subsets of circulating primary DC have different
phenotypes with non-overlapping functions. In humans, DC are
categorized as classical DC (cDC) and pDC. Classical DC are
myeloid in origin, can be further subdivided by their expression
of CD1c+ (BDCA-1) and CD141+ (BDCA-3) and were recently
renamed cDC2 and cDC1 respectively.15-17 SlanDC are a non-
classical subset of human myeloid DC that share some character-
istics with monocytes, notably their proinflammatory properties
and association with inflammatory diseases.15,18 Recently, the
study of Villani and colleagues employed single-cell RNA sequen-
cing to refine the definition of natural DC suggesting that human
DC are even more heterogeneous than previously appreciated.19
Inman, cDC2 cells are particularly important as they are the most
abundant classical myeloid DC, produce the Th1-polarising cyto-
kine IL-12, efficiently cross-present antigens and activate T-helper
1 (Th1) and CD8+ cytotoxic T lymphocyte (CTL) responses.20 In
contrast to cDC1 cells, that exhibit potent ability to cross-present
antigen, cDC2 are over 10-times more frequent in the periphery
and this makes them (and pDC) viable candidates for adoptive
immunotherapy. Importantly, recent advances in clinical-grade
cell isolation technology mean that cDC2 and pDC (but not
cDC1) can be harvested from leukapheresis using magnetic cell
sorting. This therefore provides an opportunity for the next gen-
eration of DC-based adoptive immunotherapy with natural DC.21
Indeed, in addition to functional superiority over moDC, circulat-
ing DC have the distinct advantage that they do not require
lengthy laboratory differentiation, but rather can immediately be
loaded with antigen andmatured. Results from a recent phase I/II
trial of adoptively transferred cDC2 in advanced melanoma
patients produced de novo, antigen-specific T cell responses, and
objective tumor regression.22
A previous study by Gousias and colleagues showed
decreased numbers of circulating DC in glioma patients.23
However, the phenotypic characteristics of the DC subsets, and
their function was outside the scope of that study. There is an
urgent need to understand the function of circulating DC func-
tion in GBM patients, in particular, mechanisms to alleviate
tumor mediated DC dysfunction. Obtaining this information is
important for future considerations of the adoptive transfer of
cDC2 in adult GBM. Therefore, we determined the abundance
of circulating DC and their associated phenotypic and functional
characteristics in adult GBM patients.
The function of DC is differentially regulated by com-
plex networks of intracellular signaling pathways.24-27
Intriguingly, these pathways do not always serve the same
function in all subsets of DC. This is well illustrated by the
p38 mitogen-activated protein kinase (MAPK) pathway that
differentially controls expression of the Th1-polarising
cytokine IL-12 from moDC and cDC2.25 Inhibiting p38
MAPK (p38i) in cDC2, but not moDC, results in high
levels of IL-12 in the absence of IL-10.25 This phenotype
is ideally suited to promote the Th1 responses required for
optimal priming of cytotoxic T lymphocytes (CTL) and the
activity of NK cells.28,29
Here we show a novel detailed analysis of circulating DC
subsets in patients with GBM. Furthermore, we demonstrate
for the first time that tumor mediated DC dysfunction can be
reversed in heavily treated patients by p38i of myeloid DC.
Importantly, in this patient group, dexamethasone mediated
dysfunction is also reversed using p38i. This discovery paves
the way for the next generation adoptive therapy using p38i-
treated autologous circulating DC to treat GBM patients.
Results
Patient characteristics
To explore if there were sufficient circulating DC numbers for
autologous vaccine treatment we recruited patients at various
stages of treatment (Table 1). The cohort was typical for GBM
patients undergoing active treatment. Sixty-nine percent were
taking steroids, while all but two patients were undergoing
treatment with either chemotherapy and/or radiotherapy.
Sixty-three percent had the residual disease and 56% had
a gross neurological deficit. The mean age of GBM patients
was 59 yr, compared to 49 yr in the healthy controls. The
median survival in the cohort was 14.0 months and had
a median performance status of one.
Table 1. Patient characteristics who were recruited for circulating DC analysis.
Glioblastoma Patients n = 16
Age (years)
Median (Range) 59 (37–74)
Sex
Male 13
Female 3
ECOG Performance Status
0 1
1 13
2 2
Treatment at DC analysis
Chemoradiation 5
Radiotherapy 2
Adjuvant Temozolomide 3
PCV chemotherapy 4
Remission 2
Type
Primary 14
Secondary 2
Dexamethasone dose
None 5
0.5-2 mg 4
>2 mg-4 mg 6
>4 mg 1
Residual Disease
Yes 10
No 6
Symptomatic Neurology
Yes 9
No 7
Survival (months)
Median (range) 14.0 (3.8–138.5)
IDH1 status
Unknown 5
Mutated 1
Wild type 10
ECOG = Eastern co-operative oncology group. PCV = procarbazine, lomustine
and vincristine chemotherapy. IDH1 = isocitrate dehydrogenase 1
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Alterations in circulating DC numbers in patients with
GBM
We determined the abundance of the major circulating DC
subsets using flow cytometry on whole blood in GBM patients
(n = 16) and healthy adults (n = 16) (Figure 1). As expected,
cDC2 and slanDC cells were the most frequent circulating DC
subsets identified. The cDC2 and pDC subsets were significantly
reduced in patients (cDC2 median 1736 vs 4975 cells/mL p =
0.028, pDC 893 vs 2287 cells/mL p < 0.001, patients vs controls,
respectively). In contrast, there were equivalent numbers of the
slanDC in patients and controls (3296 vs 3936 cells/mL, respec-
tively; p = 0.379). Themyeloid cDC1 subset had a non-significant
trend towards lower numbers (135 vs 228 cells/mL, patients vs
controls p = 0.078). Even in the context of this sample size, it was
possible to identify a proportion of patients with similar numbers
of circulating DC as healthy controls (Figure 1(b)).
We undertook a preliminary univariate analysis and found that
patients with higher circulating DC numbers had increased survi-
val (cDC2 p = 0.019; pDC p = 0.004; and cDC1 p = 0.009). Higher
numbers of cDC2were associatedwith no steroid use at the timeof
blood acquisition (p = 0.005), no residual disease (p = 0.028),
a secondary GBM (p = 0.002) and in remission (p = 0.01).
Association between reduced number of DC and
dexamethasone
An association existed between the number of circulating DC
subsets and the Dex dose at the time of blood acquisition. In
all DC subsets, there was a significant linear relationship
between increasing dose of Dex and reduced number of DC;
cDC2 p = 0.0006; pDC p = 0.0060; slanDC p = 0.0009 and
cDC2 DC p = 0.0009 (Figure 1(c)). In the cDC2 subset, the
Pearson coefficient was −0.762, indicating a strong correlation
between cell number and dose of Dex. This remained signifi-
cant after adjusting for confounders of primary or secondary
GBM and current treatment. Age, sex, residual disease, overt
neurology and performance status were not significant con-
founders in this analysis.
Altered phenotype of circulating DC
The expression of HLA-DR on patients’ circulating cDC2,
cDC1, and pDC cells was significantly lower than with healthy
controls (p = 0.009, 0.029, and 0.047, respectively; Figure 2).
Additionally, CD86 expression was significantly lower on
patients’ cDC2 cells (p = 0.01). Expression of PD-L1, was
significantly lower in GBM patients in both the cDC2 (p =
0.003) and cDC1 (p = 0.015) subsets. Overall, low HLA-DR
and/or CD86 represent a less mature phenotype of the DC.
Furthermore, immature DC stimulate T cell tolerance, and
hence this is a potential mechanism for tumor tolerance in
GBM.4,6 In contrast to the other subsets studied, the pheno-
type of slanDC was unaffected in GBM patients.
Functional impairment of cDC2 cells isolated from GBM
patients
Clinical grade isolation of the cDC2 subset is now possible,
and the utility of these cells as an autologous vaccine is
under clinical investigation in prostate cancer and
Figure 1. Enumeration of circulating DC in GBM patients and healthy controls. (a) Flow cytometry was used to enumerate circulating DC. Briefly, whole blood was
stained and red blood cells lysed prior to acquisition on a flow cytometer. (i) Shows the typical forward (FSC) and side scatter (SSC) of the leukocyte populations.
Doublet events were excluded by plotting FSC height against area (ii). The exclusion of B cells, monocytes and granulocytes were achieved by gating CD14-/19- and
side scatter low events (iii). HLA-DR high events, a hallmark of DC, were then selected (iv). Lineage markers for cDC2 (CD1c+), pDC (CD303+) (v), cDC1(CD141high),
and slanDC (Slan+) (vi) were then identified against isotype controls (purple gates). (b) Absolute numbers of circulating DC in GBM patients compared with healthy
controls.(c) Correlation of steroid dose on the day of blood acquisition to DC counts (in natural log for parametric analysis). Pearson's correlation coefficient (r) and
significance are shown. Dex dose is associated with lower numbers of all subsets of circulating DC * = p < 0.05.
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malignant melanoma.22,30 The capacity to produce IL-12 to
support Th1-dependent CTL responses is an important
feature of cDC2 cells.28,31 When cDC2 were isolated from
patients (n = 6) and healthy controls they secreted hetero-
geneous amounts of IL-10 and IL-12 (Figure 3). IL-12
secretion from cDC2 was significantly impaired in GBM
patients (median 6541 vs 322 pg/mL, respectively; p =
0.0245). However, IL-10 secretion was equivalent, with
a median of 108 pg/mL in healthy volunteers compared
to 41 pg/mL (ns). Overall, the ratio of IL-12: IL-10, which
determines CD4 + T cell polarisation, significantly favored
Th1 response in healthy controls compared to GBM
patients (p = 0.032).32 This represents an impairment in
GBM patients to orchestrate appropriate anti-tumor
immune responses.
Exposure of healthy DC to tumor lysate (TL) or Dex
replicates DC dysfunction observed in GBM
To investigate factors contributing to DC dysfunction in
GBM, we tested the hypothesis that Dex or GBM tumor
lysate (TL) altered the IL-12/IL-10 cytokine balance of
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Figure 2. Circulating DC have altered phenotype in GBM patients compared to healthy controls. DC were analyzed by flow cytometry as in Figure 1. Subsequently,
the expression of HLA-DR, CD86, and PD-L1 was determined. The change in median fluorescence intensity (MFI) was calculated by subtracting the MFI of the
phenotype marker from its isotype control. (a) shows lower HLA-DR, CD86 and PD-L1 expression in cDC2 of patients compared to controls. There was also lower HLA-
DR expression in pDC (b) and cDC1 (d). *p < 0.05.
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cDC2. The secretion of IL-12 from healthy cDC2 (12309
pg/mL) was significantly suppressed following exposure to
either Dex (3050 pg/mL p = 0.0094) or TL (1294 pg/mL
p = 0.0008; Figure 4). Furthermore, whilst Dex had no
significant impact on IL-10 (p = 0.1187), exposure to TL
increased its secretion from 121.4 pg/mL to 200.3 pg/mL
(p = 0.0044). Overall these factors significantly skewed the
cytokine release away from a classical Th1-polarising pro-
file (Dex p = 0.0094 and TL p = 0.0008).
Inhibition of p38 MAPK reverses Dex and TL induced
dysfunction in cDC2
Previously we established that the p38 MAPK pathway serves
a special function in cDC2 cells where p38i increases IL-12
expression, whereas p38i inhibits IL-12 in moDC and
slanDC.25,33 We therefore hypothesized that inhibition of
p38 MAPK in cDC2 would reverse the immunosuppressive
effects of Dex and TL and initially characterized the impact of
selective p38 MAPK inhibitors on the p38-MK2 pathway.
Activation with Poly I:C/R848 increased phosphorylation of
p38 MAPK and its downstream target, MK2, by 30 min
(Figure 5(a)). As expected, BIRB0796 (1 µM) did not mark-
edly inhibit p38 phosphorylation but inhibited p38 function
as shown by the ablation of MK2 phosphorylation (Figure 5
(a)). To confirm that inhibition of MK2 phosphorylation was
a class-effect for selective p38 inhibitors and not restricted to
BIRB0796 we determined that a second selective p38 MAPK
inhibitor, VX745, also prevented p38 MAPK function. When
isolated cDC2 were treated with 1-10 µM VX745 MK2 phos-
phorylation was prevented (Figure 5(b)). Relative quantifica-
tion of Western blots from three independent donors
confirmed the negative impact of BIRB0796 or VX745 on
the p38-MK2 pathway (Figure 5(bii and iii). Treatment of
cDC2 cells with 1 µM of either p38 MAPK inhibitor enhanced
IL-12 secretion (p < 0.05 comparing PolyI:C/R848 alone to 1
µM p38 MAPK inhibitor, Figure 5(c)). Concentrations of
VX745 >1 µM did not further enhance cytokine levels and
at 10 µM ablated the response.
Inhibition of p38 MAPK significantly increased IL-12
expression in both Dex (from median 3050 to 8555 pg/mL;
p = 0.0011) and TL treated DC (from median 1294 to 9314
pg/mL; p = 0.0175). Furthermore, p38i reduced secretion of
the regulatory cytokine IL-10 (Dex median 176.9 to 39 pg/mL;
P = 0.0019, TL median (200.3 to 45.3 pg/mL; p = 0.0006). As
such, inhibition of p38 MAPK skewed the cytokine release
profile of cDC2 towards a pattern associated with Th1
responses (Figure 6(a,b)).
The functional activity of p38i cDC2 was also determined
using MLR. When healthy donor cDC2 were exposed to Dex
or TL, T-cell proliferation was significantly suppressed (p =
0.0085 and p = 0.0495, respectively). However, inhibition of
p38 MAPK restored the capacity of Dex or TL-treated DC to
stimulate T-cell expansion (p < 0.0001 and p < 0.0001,
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Figure 4. cDC2 cytokine release from healthy volunteers is skewed when exposed to Dex and TL. cDC2 were isolated from healthy volunteers (n = 9). DC were
exposed ex-vivo to Dex or TL prior to maturation with polyI:C and R848. Cytokines were measured 24 hrs later by ELISA. Dex and TL exposed DC had significantly
suppressed IL-12 secretion compared to mature DC (mDC) (a). TL exposure also significantly increased the immunosuppressive cytokine IL-10 secretion (b). Overall
the ratio of IL-12:IL-10 secretion by Dex- and TL-cultured DC was significantly skewed away from Th1 polarisation, in comparison to mDC (c). *p < 0.05.
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respectively) (Figure 6(d)). Exposure of cDC2 to Dex or TL
suppressed IFNγ production in the MLR. However, inhibiting
p38 MAPK in cDC2 cells recovered the secretion of IFNγ in
the MLR to levels markedly greater than seen with control
cells. In contrast, no changes in IL-10 production were
observed (not shown). We noted that whilst HLA-DR levels
were unaffected by p38i (Figure 6(c)), there was a six-fold
increase in CD86 expression (p = 0.001).
P38 MAPK inhibition of GBM patients cDC2 recovers
cytokine function
Having established a model of cDC2 dysfunction in GBM and
recovery by p38i in healthy donor cells, we investigated the con-
sequence of inhibiting p38 MAPK in GBM patient-derived cDC2
cells. A further six patients were recruited undergoing first-line
treatmentwith either radiotherapy (one patient), chemoradiother-
apy (four patients) or adjuvant Temozolomide (n = 1), had expo-
sure toDex (n=4) and residual disease (n= 5) and cDC2 cellswere
isolated with >95% purity.
The median number of isolated cDC2 obtained was 3625 cells/
mL (range 1,125–7,160 cells/mL), which comprised 0.52% of the
peripheral blood mononuclear cells (PBMC), range 0.35–1.50%.
Inhibition of the p38 MAPK pathway resulted in a favorable
alteration in the balance of cytokines produced by activated cells
(Figure 7). Interleukin-12 secretion significantly increased from
a median of 321.9 to 920.6 pg/mL (P = 0.0312) upon treatment
with p38i. The secretion of IL-10 was low (41.1 pg/mL) and
unaffected by p38i (35.6 pg/mL, ns). Importantly, after p38i, the
ratio of IL-12:IL-10 was skewed in favor of Th1 responses and was
similar to that found in isolated healthy donor cDC2 (Figure 7(a)).
Furthermore, the T-cell stimulatory capacity of p38i cDC2 from
patients was enhanced (Figure 7(bi), with increased proliferation
and IFNγ release from the MLR driven by matured p38i-cDC2,
compared to that stimulated bymatured cDC2 only (Figure 7(bii).
IL-10 secretion remained unaffected (Figure 7(biii).
Discussion
There is an urgent need for new therapies to treat patients with
advanced GBM. This is the first detailed analysis focusing on the
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abundance, phenotype, and function of circulating DC in GBM.
Furthermore, we go on to demonstrate a mechanism for rescu-
ing dysfunction with clear therapeutic potential for the next
generation of dendritic cell immunotherapy.
We found that there were fewer circulating cDC2 and pDC
cells, and a trend towards fewer cDC1 in GBM patients, whilst
the slanDC subset were unaffected. This is in keeping with less
detailed data on circulating DC numbers in GBM patients.23,34
A cohort of cancer patients, including six with GBM, were found
to have suppressed numbers of CD11c+ and CD123+ DC
subsets.34 Since that study, CD11c+ DC have been further
divided into the cDC2 (CD1c+) and cDC1 (CD141+) subsets
analyzed in our study. This is relevant since we now appreciate
the specialized function of individual DC subsets.15-17,19
Furthermore, we employed amethodology withminimalmanip-
ulation in which cells were stained in whole blood and avoided
errors introduced by PBMC isolation in the aforementioned
study. Importantly we only required 4 ml of blood for our
study, therefore this allowed more accurate measurement of
both the relative frequency and absolute number of DC in
blood. Another group also looked at the cDC2, cDC1 and pDC
subsets in a cohort of gliomas which included 17GBMpatients.23
Our findings are supportive of theirs, with suppressed cDC2 and
pDC number. However, we were able to perform phenotypical
evaluation including CD86, HLA-DR, and PD-L1. We found the
phenotype of circulatingDC subsets was altered in GBMpatients
with significant reductions in HLA-DR and CD86 expression.
A lowHLA-DRand/orCD86 expression represents an immature
DC phenotype and would reasonably be expected to result in
T cell tolerance.6,7 Furthermore, our novel data on CD86 and
PD-L1 expression is important, not just for determining their
maturation status, but in the context of immunotherapy cur-
rently targeting co-stimulatory/regulatory ligand pairs.
The use of Dex in GBM is independently associated with
reduced effectiveness of treatment and overall survival.9,35
Indeed, in other settings the immune system plays a vital role
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Figure 6. p38i restores the IL-12:IL-10 balance from the Dex or TL treated cDC2. (a): Reversal of the suppressive effects of Dex. cDC2 isolated from healthy volunteers
exposed to Dex with/or without p38i (n = 9) showed significantly higher IL-12 (i), reduced IL-10 (ii) and a favorable skewing towards Th1 polarisation with p38i (iii).
Figure 6 (b): Reversal of adverse effects of TL on cytokine. Healthy donor cDC2 (n = 9) exposed to TL showed higher IL-12 (i), reduced IL-10 (ii) and a favorable
skewing towards Th1 polarisation with p38i (iii). (c): Improved phenotype of DC with p38i treatment. Isolated cDC2 were matured with R848 and polyI:C with/or
without pre-incubation with p38i (n = 4). CD86 expression was significantly increased in p38i cDC2 compared to matured cDC2 (i) while HLA-DR expression was
unchanged. (d): Enhanced T-cell stimulatory capacity of DC following p38i. Isolated cDC2 were exposed to Dex and TL with/without p38i. DC were then co-cultured
with lymphocytes for 5 days (n = 3). p38i restored and enhanced cDC2 stimulatory capacity in MLR above normal levels (mDC). Data from a representative donor is
shown (i and iii). A significant increase in IFNγ secretion suggested a Th1 polarisation results as shown in the representative example (ii and iv).
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in the success of chemotherapy and radiotherapy which induces
immunogenic cell death.36 Dex is immunosuppressive and stu-
dies in the transplantation field showed the exposure of human
cDC2 to Dex induces tolerogenic DC.37 The present study
represents one of the first functional studies of the cDC2 subset
in GBM and identifies suppressed IL-12 responses in these
patients. The decreased IL-12:IL-10 ratio in activated cDC2
would be predicted to result in weaker Th1 and NK responses.
Whilst this study does not attempt to define the driving force
behind these changes, we successfully replicated this phenotype
by exposing healthy cDC2 to Dex or TL.
We established a favorable effect of p38i in cDC2 for IL-12
production, increased CD86 expression and capacity to promote
T-cell proliferationwith high levels of IFNγ. However, it remains
to be determined what the impact of p38i is on other important
aspects of cDC2 function including antigen-uptake, antigen-
processing, and cross-presentation to T-cells, and migratory
capacity. Further studies are currently underway to address
these important features of DC biology. A more detailed under-
standing of the impact of inhibiting specific signaling pathways
in natural DC should include detailed transcriptional analysis
(RNASeq) and important information could be obtained from
patients receiving oral p38i for other inflammatory conditions
using single-cell RNASeq on whole blood or isolated cDC2.
The canonical understanding of the p38 MAPK pathway is
that it promotes expression of inflammatory genes.38
BIRB0796 is a potent inhibitor of all 4 p38i isoforms with 330-
fold greater selectivity versus c-Jun N-terminal kinase 2, weak
inhibition for c-RAF, and insignificant activity against extra-
cellular regulated kinase.39 It also has a particularly slow
dissociation rate constant and this is thought to contribute
to its potency. In cDC2, the p38 pathway represses IL-12
expression and consequently inhibition of p38 increases IL-
12 secretion.25 We made similar findings with additional
selective p38 MAPK antagonists, VX-745 and SB203580 (not
shown) showing that our findings are consistent with a p38
MAPK inhibitor “class-effect” and not unique to one com-
pound. Newer compounds with improved safety profiles have
now been developed (e.g. PH-797804) and these may be
suitable candidates for phase I studies of adoptively trans-
ferred, p38i cDC2 cells in GBM.40 In consideration of
a clinical trial of p38 MAPK inhibited, adoptively transferred
cDC2 it is likely that alternate MAPK inhibitors would be
employed that are highly specific for p38 MAPK and are
irreversible/have slow off-rate. It is worth mention that pre-
liminary experiments (n = 2) show that when cDC2 were
briefly (1 hr) exposed to BIRB0796 (1 uM), washed and
activated, their profile of IL-12/10 expression conformed to
that obtained with chronic exposure to MAPK inhibitor (data
not shown). Importantly, in contrast to most clinical p38i that
are typically formulated for oral or inhaled delivery, our
proposed clinical study will require a GMP compound already
suitably formulated (i.e. i.v.) for delivery to isolated cDC2 cells
in a cell-processing facility.
Obtaining sufficient cell numbers remains a persistent chal-
lenge in the development of adoptive immunotherapy with circu-
latingDC.Given that leukopheresis typically yields 7 × 109 PBMC,
and in our hands, isolated cDC2 comprised 0.52% of PBMC, we
could expect 3.6 × 107 cDC2 per leukopheresis.41 A recent mela-
noma phase I trial with cDC2 cells used 3–10 × 106 cells per
treatment.22 Hence, even though cDC2 numbers are decreased
in GBM patients, it would be reasonable to expect to be able to
isolate sufficient cells to undertake adoptive immunotherapy.
Primary, circulating DC are attractive candidates for next-
generation adoptive immunotherapy. They are functionally
superior to moDC42 and do not require lengthy ex-vivo dif-
ferentiation, with vital cost and time implications. Clinical
development of cDC2 for cancer immunotherapy is already
in phase I trials and is resulting in some exciting clinical
responses.22,30 Future studies may also combine this approach
with immune checkpoint blockade. The importance of DC
function for checkpoint blockade was established with mice
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Figure 7. Patients cDC2 function is improved by inhibiting p38 MAPK. (a): p38i skews patients’ cDC2 to favorable cytokine release profile: Treatment of GBM patients’
(n = 6) cDC2 with p38i (mDC+p38i) (i) improved IL-12 secretion, (iii) and restored the IL-12: IL10 balance without affecting IL-10 (ii), compared to maturation alone
(mDC). (b): Patient p38i cDC2 had the superior proliferative capacity with IFNγ signature: cDC2 isolated from GBM patients were treated ex-vivo with p38i and
matured for 24 hrs. DC were then co-cultured with allogeneic peripheral blood lymphocytes in a mixed lymphocyte reaction for 5 days. Proliferation data from
a representative donor is shown. DC stimulatory capacity was superior with p38i treatment (i) and the resulting supernatant was rich in IFNγ (ii) and low in IL-10 (iii).
*p < 0.05.
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deficient in cDC that failed to respond to checkpoint
inhibitors.43 In humans, histological analysis of PD-L1 treated
melanoma patients showed responders had pre-existing
immunity against the tumor. This was defined as a tumor
rich in CD8 + T-cells, an IFNγ CTL signature and PD-L1
expression.44 Hence using DC vaccination to increase the pool
of antigen-specific CTL is likely to increase responses to anti-
PD-1/PDL-1 antibodies. Our current investigations therefore
highlight the potential of combining p38i-treated cDC2 with
clinical immune checkpoint blockade antibodies. This is of
particular importance given that PD-1 inhibitor monotherapy
has failed to show a survival benefit in GBM patients.45
In summary, we describe suppression of the number, pheno-
type, and function of circulating DC subsets in patients with
GBM. Furthermore, patients’ cDC2 cells had an immature phe-
notype and only weakly stimulated lymphocyte proliferation.
Dexamethasone and tumor are shown to be causative factors
contributing to DC dysfunction and importantly, the loss of
function was recovered by inhibiting p38 MAPK prior to DC
activation. We therefore propose the next generation of DC
vaccines in GBM include enhanced p38i cDC2. In this regard,
we will now undertake a clinical trial of p38 MAPK-inhibited
cDC2 cells in adults with advanced cancer, the results of which
will provide key insights into the immune systemof these patients.
Patients and methods
Healthy donors and GBM patients
Studies were undertaken with ethical approvals granted by
The University of Nottingham Research Ethics Committee;
reference: 10/H0405/6, BT20052010, and 09/H0408/75. This
study’s involvement with human subjects complies with the
Declaration of Helsinki.
Adult participants were recruited from Nottingham
University Hospital National Health Service (NHS) Trust
and selected based on a diagnosis of GBM. Healthy controls
were selected to be age- and sex-matched to recruited
patients. Participants were consented prior to sample collec-
tion and sample use was restricted to this study. Patient
characteristics are shown in Table 1.
Enumeration of circulating dendritic cell subsets
To measure the abundance of circulating subsets of DC, freshly
derived heparinized whole blood was incubated with combina-
tions of appropriate test or control antibodies. The test antibodies
included CD14-PerCP/Cy5.5 (325622), CD19-PerCP/Cy5.5
(302230), CD1c-APC (331524), CD141-APC (344106), CD303-
FITC (354208 – all Biolegend), Slan (M-DC8)-FITC (130-093-
178), HLA-DR-Vioblue (130-095-293 – both Miltenyi, UK),
CD86-PE (12–0869-42) and PD-L1-PECy7 (25-5983-42 – both
eBioscience). Respective isotype controls included IgG2a-FITC
(400210), IgG1κ-APC (400122 – both Biolegend), IgG2a-Vioblue
(130-094-671), IgM-FITC (130-093-178 – bothMiltenyi), Ig2b-PE
(12-4732-42) and IgG1κ-PECy7 (25-4714-42 – both eBioscience).
Red blood cells were lysed in Red Cell Lysis buffer (eBioscience)
and cells washed three times before re-suspension inMACSQuant
Running Buffer (Miltenyi) and acquisition using a MACSQuant
flow cytometer (Miltenyi).
The data was analyzed using FlowJo as follows. Briefly,
following exclusion of doublet events, thresholds and box
gates were objectively established by extensive use of isotype
and fluorescence-minus-one (FMO) controls. Lineage nega-
tive (Lin-) (low side scatter, CD14-, CD19-), HLA-DR+ cells
were selected for further analysis as follows: cDC2 cells were
characterized as CD1c+, cDC1 subset was CD141+, and pDC
were defined as CD303+ . The slanDC subset was 6-Sulfo
LacNAc (Slan)+. A representative example of flow-cytometry
gating is shown in Figure 1.
The absolute number of circulating DC per mL blood, and
their relative frequency were calculated. Events were normal-
ized by subtracting the number of events in FMO gates from
test gates. Because of the scarcity of circulating DC subsets,
consideration was given to the minimum number of acquired
events for statistical validity.46,47 In consideration of variabil-
ity of measuring rare cell events in whole blood we undertook
a repeated analysis of control samples to ensure the assay
delivered a coefficient of variance (CV) of approximately 10%.
Isolation and culture of cDC2 cells
Peripheral blood mononuclear cells (PBMC) were separated
from the whole blood using density centrifugation over
Histopaque 1077 (Sigma, UK). Myeloid cDC2 cells were iso-
lated using an anti-CD1c kit (Miltenyi) following the manu-
facturer’s instructions. Briefly, following depletion of B cells,
CD1c+ cells were positively selected, washed, and counted.
Cells were seeded in 96-well plates at 104/well in RPMI-1640
with L-glutamine (Sigma, UK) containing 10% fetal calf
serum (FCS), 1% sodium pyruvate (Sigma, UK) and 10 U/
mL granulocyte-macrophage colony stimulating factor (GM-
CSF, Peprotech, UK). Viability and purity were routinely
determined to be >95%. Antibiotics were not used.
Tumour-derived lysate (TL)
A panel of established human GBM cell lines (U87, LN18,
LN229 obtained directly and recently from ATCC) were grown
in 10-layer factory flasks (Corning Costar, Netherlands) and
harvested by trypsinization after three days. The cells were
then washed by centrifugation (300 g) and re-suspended at
107/mL in RPMI-1640. Lysate was prepared from passage 5–8
by five cycles of freeze-thaw as previously described.48 All cells
were routinely tested for mycoplasma prior to lysate preparation
following the manufacturer’s protocol (R&D Systems 322361)
and found to be negative.
Response of cDC2 to Dex and TL
Immature cDC2 from healthy donors were plated in 96 well
plates as described above. After resting for 30 min, the p38
MAPK selective antagonist BIRB0796 (Selleckchem, UK) was
added to appropriate wells (1 μM) prior to addition of Dex
(10−6M) or TL (ratio DC:TL 1:50). Cells were then incubated
for 1 h prior to maturation with R848 2.5 μg/mL (InvivoGen,
USA) plus poly I:C 20 μg/mL (Sigma, UK). Supernatants were
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harvested after 24 h and their cytokine content assayed. All
experimental conditions were undertaken in triplicate.
Cytokine ELISA
Supernatants were assayed by ELISA for IL-12 (BD
Bioscience, UK) and IL-10 (R&D Systems, UK) according to
the manufacturer’s instructions. Assays did not significantly
cross-react with other proteins, and the sensitivities were 7.8
and 15 pg/mL, respectively.
Western blotting
The activity of BIRB0796 and VX745 (Tocris) was confirmed
by western blotting for the downstream target phospho-MK2.
Isolated cDC2 cells were plated in DC medium containing
GM-CSF. After resting, cells were treated with 1 μM
BIRB0796 (or the indicated concentration of VX745) for 1
hr, stimulated with Poly I:C/R848 then lysed in radio-
immunoprecipitation assay buffer (RIPA) (Sigma) containing
protease inhibitor cocktail, phosphatase inhibitor cocktail 2
and 3 and Benzonase endonuclease (all Sigma) on ice for 1
h. Proteins were resolved by SDS-PAGE electrophoresis in
10% Tris/glycine gels and transferred to nitrocellulose.
Membranes were blocked (5% milk powder (w/v) in PBST
(PBS-0.1% (v/v) Tween 20)), probed with primary antibodies
overnight at 4°C whose binding was detected with secondary
antibodies in 1% milk powder (w/v) in PBST. Rabbit anti-
human phospho-MK2(T334) and mouse anti-human β-actin
(Sigma) were detected with donkey anti-rabbit-800 and anti-
mouse-680 (LiCor) and imaged by LiCor Odyssey SA. Semi-
quantitative analysis was undertaken with Odyssey software
normalizing to β-actin.
Mixed lymphocyte reaction (MLR)
The impact of inhibiting p38 MAPK on the ability of DC to
drive T-cell proliferation was determined. DC were cultured
with peripheral blood lymphocytes (PBL) in 96-well plates in
T-cell medium (RPMI-1640, 10% FCS, non-essential amino
acids, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES) and sodium pyruvate). Where specified, DC were
co-cultured with Dex (10−6M) and TL (DC:TL 1:50). At day 5,
tritiated thymidine (0.5μCi/well) was added during the final
18 h of culture and its incorporation determined using liquid
scintillation counting. Supernatants were analyzed by ELISA
for IFNγ (BD bioscience) and IL-10.
Statistical analysis
Results were statistically analyzed using student’s t-test when
normally distributed or normal when transformed using
either ln x or 1/x. Otherwise, Mann–Whitney analysis was
used for non-parametric data. Freidman tests were used,
where multiple paired comparisons of non-parametric cyto-
kine data were required and Wilcoxon test for single group
paired analysis. Cut-off of P < 0.05 was interpreted as statis-
tically significant.
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